Aurora Cannabis to disclose marijuana testing data to ease public concerns - Action News
Home WebMail Sunday, November 10, 2024, 11:42 PM | Calgary | 0.4°C | Regions Advertise Login | Our platform is in maintenance mode. Some URLs may not be available. |
Business

Aurora Cannabis to disclose marijuana testing data to ease public concerns

Medical marijuana firm Aurora Cannabis Inc. has announced a new disclosure process for its quality control data, which it says will assure clients of the purity of its products.

Pesticide contamination in Canadian medical marijuana has led to recalls, proposed lawsuits

Aurora Cannabis Inc., a licensed medical marijuana producer, says a new disclosure process for third-party quality control testing will assure clients of the purity of its products. (Julien Lecacheur)

Medical marijuana firm Aurora Cannabis Inc. has announced a new disclosure process for its third-party quality control testing, which it says will assure clients of the purity of its products.

That announcement comes amid growing concern over recalls of contaminated marijuana sold by Health Canada-approved producers.

Every product sold by Aurora now comes with a certificate of analysis provided by cannabis testing laboratory Anandia Labs.

Aurora, which is based inCremona, Alta., and has offices in Vancouver,says the certificates will show that its products have "been analyzed with high accuracy for potency and passed Anandia's rigorous testing procedures for the presence of contaminants."

The certificates have been made available on the Aurora website and on its mobile app for ordering medical marijuana.
The first page of a certificate of analysis from Anandia Labs shows test results for the 'Odin' strain of marijuana produced by Aurora Cannabis. (Aurora Cannabis/Anandia Labs)

AnandiaLabs says it tests for "51 pesticides and plant growth regulators, as well as other contaminants such as bacteria and heavy metals."

"It is imperative that patients have confidence in the safety of the products they consume, and in the integrity of the medical cannabis system," Aurora chief executive Terry Booth said in a release.

Booth said his company's move "will raise the bar for the entire sector, and offer a model for other companies to follow."

Reports of reactions

Aurora's move follows a series of pesticide-related recalls at Canadian medical marijuana producers Organigram and Mettrum and a January recall by Aurora itself, which sold some Organigram products to its customers.

Since those recalls,Health Canada has received 13reports of adverse reactions as of March 6. Health Canada spokesman Andr Gagnontold CBC News those reports "are not, on their own, proof of a specific substance causing a reaction."

A January recall notice from medical marijuana producer Organigram. (Elizabeth Chiu/CBC)

In January, New Brunswick-based OrganigramInc. issued a voluntaryrecall of products sold in 2016 after they were found to contain low levels of the pesticidesmyclobutanil andbifenazate, both of which aren't authorized by Health Canada for use on cannabis plants.

Health Canada said it received a total of four adverse reaction reports involving Organigram products, with symptoms including "weight loss, nausea, vomiting, throat irritation, and respiratory tract irritation." Three of those reports were received after the recall began.

Organigramis nowpreparing to defend itselfagainst a proposed class action lawsuit over the use of pesticides, andlost its organicstatusfromorganic certificationorganizationEcocert.

Aurora Cannabis voluntarily recalled seven lots of Organigram product that it sold to customers under the Auroraname. Four adverse reaction reports, all sent to Health Canada about Aurora products after the recall was announced, noted symptoms including "pain, confusion, dysphoria, and tiredness."

In December, Ontario-based Mettrum Health Corp. voluntaryrecalled products produced earlier that year after finding trace amounts ofmyclobutanil. Mettrum had also recalled some products in Novemberafter detectingpyrethrins, another unapproved pest-control product.

Health Canada said it received 16 adverse reaction reports regarding Mettrum products, six of them after the recall began. The reports described symptoms including "dizziness or balance disorders, nausea, difficulty breathing, heart palpitations, diarrhea, sleep disturbance, gastrointestinal issues, pain and discomfort, swelling, movement disorder, and disturbances in thinking and perception."

Mettrum was acquired byOntario-based Canopy Growth Corp., Canada's largest authorized producer of medical marijuana, in February of 2017. Later that month, Canopy Growth CEO Bruce Linton apologized to customers for the Mettrum recall, and said his company had improved its quality control practices.

On Monday, a Toronto law firm issued a proposed class action lawsuit against Mettrum over the use of unauthorized pesticides. Canopy Growth says it will defend itself against any lawsuits related to the Mettrum recalls.

Following the recalls at Organigram and Mettrum, Health Canada said it was beginning random testing of products from licensed producers.

With files from Elizabeth Chiu